Home » Cancer Therapy » Clay Siegall’s Drive To Redefine Cancer Therapy

Clay Siegall’s Drive To Redefine Cancer Therapy

The field of cancer therapies has received numerous contributions from different companies in the past ten years. However, Seattle Genetics has stood out in its course to undertake extensive cancer research. Through Seattle Genetics, Dr. Clay Siegall has made advancements in cancer therapy. The company’s dominance in this field is reflected in their stock price, which has tripled over the years. As the leader of Seattle Genetics, Clay Siegall is determined to change the lives of cancer patients. Through cutting-edge research developments, Siegall has seen the company develop the first antibody drug conjugates, ADCETRIS, which was approved by FDA in 2011.

Today, ADCETRIS is being sold in over 60 countries. Siegall is dedicated to promoting the drug in an effort to ensure that the biomedical community prioritizes cancer therapies in the coming years. His steadfast devotion to cancer therapy motivated him to push for the FDA approval. He remains optimistic that ADCETRIS will be made available to many patients around the world. He has played an instrumental role in enhancing company’s funding. Recently, he received more than $1.2 billion through public and private funding, which has enhanced their advancements in cancer treatments using the most innovative technologies.

Clay B. Siegall, PhD is a co-founder of Seattle Genetics. He serves as president, CEO and chairman of the Board. With a deep passion to improve the lives of cancer patients, Clay built Seattle Genetics on the foundation of thorough scientific research and drug development practices. The company has entered into numerous collaborator programs where they are now developing more than 20 ADCs using Seattle Genetics’ technology.

Before establishing Seattle Genetics, Siegall worked for different companies, including Bristol-Myers Squibb Pharmaceutical Research Institute, National Institutes of Health and the National Cancer Institute. He is a member of the boards of directors of Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and Washington Roundtable. His distinguished career has seen him earn recognition and several awards, including the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. Clay is a committed author having over 70 publications. He is a graduate of George Washington University and the University of Maryland.